Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 19/20 | 0.55 |
| ▸ | HCRTR2 | O43614 | 12/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1571858 | 0.82 | HCRTR1 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL15184286 | 0.80 | HCRTR1 (0.60) | HCRTR1HCRTR2 | |
| SCHEMBL16279291 | 0.80 | HCRTR1 (0.60) | HCRTR1HCRTR2 | |
| SCHEMBL6980865 | 0.79 | KDM4E (0.61) | HCRTR1HCRTR2CNR1CNR2 | |
| SCHEMBL983914 | 0.79 | HCRTR1 (0.43) | HCRTR1HCRTR2 | |
| SCHEMBL982052 | 0.79 | HTR4 (0.48) | — | |
| SCHEMBL20040280 | 0.77 | HCRTR1 (0.61) | HCRTR1HCRTR2 | |
| SCHEMBL20040278 | 0.77 | HCRTR1 (0.61) | HCRTR1HCRTR2 | |
| SCHEMBL981738 | 0.74 | HCRTR1 (0.80) | HCRTR1HCRTR2 | |
| SCHEMBL15184248 | 0.74 | HCRTR1 (0.71) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236801-B2 | 2-aza-bicyclo[2.2.1]heptane derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-08-07 | — | — | US | disclosed |
| EP-2247586-B1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-04-25 | — | — | EP | disclosed |
| US-20110009401-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-01-13 | — | — | US | disclosed |
| EP-2247586-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009104155-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009401-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | HCRTR2, HCRTR1, HCAR2 | HCRTR1 2/4885HCRTR2 1/4885CNR1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.